Research ExplorerPublicationsExperimental models and therapeutic approaches for HBV

Experimental models and therapeutic approaches for HBV

Standard

Experimental models and therapeutic approaches for HBV. / Dandri, Maura; Lütgehetmann, Marc; Petersen, Jörg.

In: SEMIN IMMUNOPATHOL, Vol. 35, No. 1, 01.01.2013, p. 7-21.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Dandri, M, Lütgehetmann, M & Petersen, J 2013, 'Experimental models and therapeutic approaches for HBV', SEMIN IMMUNOPATHOL, vol. 35, no. 1, pp. 7-21. https://doi.org/10.1007/s00281-012-0335-7

APA

Dandri, M., Lütgehetmann, M., & Petersen, J. (2013). Experimental models and therapeutic approaches for HBV. SEMIN IMMUNOPATHOL, 35(1), 7-21. https://doi.org/10.1007/s00281-012-0335-7

Vancouver

Dandri M, Lütgehetmann M, Petersen J. Experimental models and therapeutic approaches for HBV. SEMIN IMMUNOPATHOL. 2013 Jan 1;35(1):7-21. https://doi.org/10.1007/s00281-012-0335-7

Bibtex

@article{f14da8aa9c3e45a4adf92840194f00df,
title = "Experimental models and therapeutic approaches for HBV",
abstract = "Liver disease associated to persistent infection with the hepatitis B virus (HBV) continues to be a major health problem of global impact. In spite of the existence of an effective vaccine, approximately 360 million people are chronically infected worldwide, who are at high risk of developing liver cirrhosis and hepatocellular carcinoma. Although current therapeutic regimens can efficiently suppress viral replication, the unique replication strategies employed by HBV permit the virus to persist within the infected hepatocytes. As a consequence, relapse of viral activity is commonly observed after cessation of treatment with polymerase inhibitors. The narrow host range of HBV has hindered progresses in understanding specific steps of HBV replication and the development of more effective therapeutic strategies aiming at achieving sustained viral control and, eventually, virus eradication. This review will focus on summarizing recent advances obtained with well-established and more innovative experimental models, giving emphasis on the strength of the different systems as tools for elucidating distinct aspects of HBV persistence and for the development of new therapeutic approaches.",
keywords = "Animals, Antiviral Agents, Carcinoma, Hepatocellular, Cell Line, Hepatitis B, Hepatitis B Vaccines, Hepatitis B virus, Humans, Interferon-alpha, Liver Neoplasms, Mice, Mice, Transgenic, Pan troglodytes, Polyethylene Glycols, Recombinant Proteins",
author = "Maura Dandri and Marc L{\"u}tgehetmann and J{\"o}rg Petersen",
year = "2013",
month = jan,
day = "1",
doi = "10.1007/s00281-012-0335-7",
language = "English",
volume = "35",
pages = "7--21",
journal = "SEMIN IMMUNOPATHOL",
issn = "1863-2297",
publisher = "Springer",
number = "1",

}

RIS

TY - JOUR

T1 - Experimental models and therapeutic approaches for HBV

AU - Dandri, Maura

AU - Lütgehetmann, Marc

AU - Petersen, Jörg

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Liver disease associated to persistent infection with the hepatitis B virus (HBV) continues to be a major health problem of global impact. In spite of the existence of an effective vaccine, approximately 360 million people are chronically infected worldwide, who are at high risk of developing liver cirrhosis and hepatocellular carcinoma. Although current therapeutic regimens can efficiently suppress viral replication, the unique replication strategies employed by HBV permit the virus to persist within the infected hepatocytes. As a consequence, relapse of viral activity is commonly observed after cessation of treatment with polymerase inhibitors. The narrow host range of HBV has hindered progresses in understanding specific steps of HBV replication and the development of more effective therapeutic strategies aiming at achieving sustained viral control and, eventually, virus eradication. This review will focus on summarizing recent advances obtained with well-established and more innovative experimental models, giving emphasis on the strength of the different systems as tools for elucidating distinct aspects of HBV persistence and for the development of new therapeutic approaches.

AB - Liver disease associated to persistent infection with the hepatitis B virus (HBV) continues to be a major health problem of global impact. In spite of the existence of an effective vaccine, approximately 360 million people are chronically infected worldwide, who are at high risk of developing liver cirrhosis and hepatocellular carcinoma. Although current therapeutic regimens can efficiently suppress viral replication, the unique replication strategies employed by HBV permit the virus to persist within the infected hepatocytes. As a consequence, relapse of viral activity is commonly observed after cessation of treatment with polymerase inhibitors. The narrow host range of HBV has hindered progresses in understanding specific steps of HBV replication and the development of more effective therapeutic strategies aiming at achieving sustained viral control and, eventually, virus eradication. This review will focus on summarizing recent advances obtained with well-established and more innovative experimental models, giving emphasis on the strength of the different systems as tools for elucidating distinct aspects of HBV persistence and for the development of new therapeutic approaches.

KW - Animals

KW - Antiviral Agents

KW - Carcinoma, Hepatocellular

KW - Cell Line

KW - Hepatitis B

KW - Hepatitis B Vaccines

KW - Hepatitis B virus

KW - Humans

KW - Interferon-alpha

KW - Liver Neoplasms

KW - Mice

KW - Mice, Transgenic

KW - Pan troglodytes

KW - Polyethylene Glycols

KW - Recombinant Proteins

U2 - 10.1007/s00281-012-0335-7

DO - 10.1007/s00281-012-0335-7

M3 - SCORING: Journal article

C2 - 22898798

VL - 35

SP - 7

EP - 21

JO - SEMIN IMMUNOPATHOL

JF - SEMIN IMMUNOPATHOL

SN - 1863-2297

IS - 1

ER -